Advertisement
Advertisement

MDGL

MDGL logo

Madrigal Pharmaceuticals, Inc. Common Stock

477.20
USD
Sponsored
+13.78
+2.97%
Feb 06, 16:00 UTC -5
Closed
exchange

After-Market

477.19

-0.01
0.00%

MDGL Earnings Reports

Positive Surprise Ratio

MDGL beat 22 of 40 last estimates.

55%

Next Report

Date of Next Report
Feb 19, 2026
Estimate for Q4 25 (Revenue/ EPS)
$316.47M
/
-$0.78
Implied change from Q3 25 (Revenue/ EPS)
+10.17%
/
-84.27%
Implied change from Q4 24 (Revenue/ EPS)
+206.30%
/
-71.22%

Madrigal Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Nov 04, 2025, MDGL reported earnings of -4.96 USD per share (EPS) for Q3 25, missing the estimate of -2.12 USD, resulting in a -133.61% surprise. Revenue reached 287.27 million, compared to an expected 252.25 million, with a 13.88% difference. The market reacted with a +7.83% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 18 analysts forecast an EPS of -0.78 USD, with revenue projected to reach 316.47 million USD, implying an decrease of -84.27% EPS, and increase of 10.17% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Madrigal Pharmaceuticals, Inc. Common Stock reported EPS of -$4.96, missing estimates by -133.61%, and revenue of $287.27M, 13.88% above expectations.
The stock price moved up 7.83%, changed from $412.35 before the earnings release to $444.64 the day after.
The next earning report is scheduled for Feb 19, 2026.
Based on 18 analysts, Madrigal Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.78 and revenue of $316.47M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement